Next-generation cancer treatment

When a doctor has a limited understanding of the complex biology of cancer, he or she often plays a game of trial-and-error, hoping to find the right medication before time runs out for the patient. Because time is often of the essence, we try our best to get it right the first time by targeting key survival mechanisms of cancer. It builds upon my deep understanding of cancer cell biology and extensive clinical experience gained over the past three decades, along with the pioneering work of my Malaysian colleague, Dr. Raymond Ngeh who, until his tragic death from COVID, was combining high-dose intravenous vitamin C with low-dose chemotherapy and achieving extraordinary results (click here to see case studies). The result of our collaboration is the advanced protocol below that combines our individual areas of expertise. Even some with “incurable” or “terminal” cancer who have failed all previous therapy, including drug trials, have had their disease transformed from a likely death sentence to a manageable “chronic illness” requiring periodic treatment.

Diet and lifestyle:

Proper diet and lifestyle lay the foundation for eradicating cancer and preventing its return. To learn more: Click here.

Once-a-week, in-office treatment:

• • High-dose intravenous vitamin C* with solamargine** and low-dose doxycycline and azithromycin, followed by carbogen breathing. This is immediately followed by…
  • Low-dose chemotherapy*** combining 3-5 synergistic drugs used for the cancer type at 10-20% of the normal dose. This is combined with inhalable molecular hydrogen, and hyperthermia to heat tumor tissue to 42°C. Due to the low dose of chemotherapy drugs, treatment is generally well tolerated with most patients experiencing no major side effects. The main side effect is nausea, and this is minimized by using ondansetron (Zofran).
  • The following morning, we administer oral cinnamaldehyde and hyperthermia. This time, heating tumor tissue to 45°C.

*We use sodium ascorbate instead of ascorbic acid. Unlike ascorbic acid, sodium ascorbate has a neutral pH and takes advantage of the cell’s intrinsic sodium-dependent vitamin C transporters (SVCT1 and SVCT2) to improve intracellular ascorbate concentration (click here).

**Solamargine is a medicinal plant com­pound with unique and highly desirable anticancer properties (click here). Unfortunately, solamargine is not available at any retail or compounding pharmacy. To give our patients access to this potentially life-saving compound, at great expense, we get it custom extracted and purified by medicinal chemists.

***A chest port or PICC line is required for intravenous chemotherapy.

Supporting oral medications and supplements:

• • Acetazolamide
  • Berberine
  • Bromelain
  • Curcumin
  • Ferulic acid
  • Fisetin
  • Ivermectin
  • Metformin
  • Nattokinase
  • Pacific yew tree extract (contains naturally-occurring taxanes)
  • Pentoxifylline
  • Piperlongumine
  • Reishi mushroom wall-broken spore powder
  • Simvastatin
  • Specialized pro-resolving mediators
  • Sulforaphane
  • Syrosingopine: This is a weak antihypertensive drug that was made by CIBA Pharmaceuticals (now Novartis) and first used in 1958. Due to poor sales, it was discontinued in 1968. Unfortunately, syrosingopine is not available at any retail or compounding pharmacy. To give our patients access to this potentially life-saving drug (click here), at great expense, we get it custom synthesized and purified by medicinal chemists.

Note: To download a copy of the daily Medication & Supplement Schedule, click here.

The scientific rationale for our protocol is broken down into these seven crucial components:

1. Block cancer energy metabolism (“starve” cancer): Metformin and syrosingopine¹

2. Promote chemosensitivity and chemoprotection, and inhibit multi-drug resistance: Ivermectin², pentoxifylline³, curcumin^4,5, reishi⁶, molecular hydrogen^7,8, and intravenous vitamin C⁹

3. Target systemic conditions and conditions in the tumor microenvironment that promote cancer growth, invasion, and metastasis; impede intratumoral distribution of anticancer compounds; and lead to immune evasion:

• • Hypoperfusion and hypoxia: Sulforaphane¹⁰, pentoxifylline¹¹, hyperthermia at 42°C¹², and carbogen¹⁴
  • Elevated tumor interstitial fluid pressure: Pentoxifylline¹¹, taxanes¹⁵, and hyperthermia at 42°C¹⁶
  • Extracellular acidification: Metformin and syrosingopine¹, and acetazolamide¹⁷
  • Chronic inflammation: Berberine¹⁸, specialized pro-resolving mediators¹⁹
  • Angiogenesis: Berberine²⁰, ivermectin²¹, pentoxifylline²², piperlongumine²³, and reishi²⁴
  • Desmoplasia (tumor fibrosis): Pentoxifylline²⁵
  • Blood coagulation and hemorheologic disturbances (elevated blood viscosity, platelet activation, red cell rigidity, microthrombi, parafibrin aggregates): Hydration²⁶, bromelain²⁷, ferulic acid²⁸, nattokinase²⁹, acetazolamide³⁰, metformin³¹, and pentoxifylline³²

4. Kill proliferating (active) cancer cells by promoting multiple death pathways. Standard anticancer therapies attempt tumor suppression mainly through the induction of apoptosis. In many cases, however, cancer cells are innately resistant to apoptosis or can adapt by acquiring the ability to escape apoptosis, thus rendering the treatment palliative and insufficient. Because cancer cells that are resistant to one type of cell death are often vulnerable to another type, we take a broad approach by promoting seven known forms of cancer cell death:

• • Apoptosis: Berberine³³, reishi³⁴, high-dose intravenous vitamin C and low-dose chemotherapy³⁵, solamargine³⁶, hyperthermia¹², and cinnamaldehyde¹³
  • Autophagy: Berberine³⁷, piperlongumine³⁸, and pentoxifylline with simvastatin to transform autophagic cancer cells into apoptotic cells³⁹
  • Ferroptosis: Acetazolamide^40,41 and piperlongumine⁴²
  • Immunogenic cell death: Berberine¹⁸, piperlongumine⁴³, reishi^44-46, intravenous solamargine³⁶, and hyperthermia at 45°C⁴⁷
  • Necroptosis: Berberine⁴⁸ and hyperthermia at 45°C¹²
  • Pyroptosis: Metformin⁴⁹ and berberine⁵⁰
  • Paraptosis: Curcumin and Pacific yew tree extract⁵¹

5. Kill senescent cancer cells and tumor stromal cells: Fisetin⁵², piperlongumine⁵³, and intravenous solamargine³⁶

6. Eradicate cancer stem cells: Intravenous vitamin C plus azithromycin and doxycycline⁵⁴

7. Promote phagocytic removal of tumor debris: Specialized pro-resolving mediators¹⁹

Monitoring treatment effectiveness:

To make sure the protocol is working as quickly as possible, we get a baseline PET/CT scan and monthly scans thereafter. We may also monitor treatment progress by getting a baseline Signatera™ test to measure ctDNA (circulating tumor DNA) level and retesting every couple of weeks. 

More about Dr. Thomas:

I have dedicated my medical career to helping can­cer patients live better and longer by providing them with cutting-edge treatment options. I have over 30 years of clinical experience. In addition to a medical degree, I have a post-doctoral master’s degree in Metabolic & Nutritional Medicine and served a fellowship in Integrative Cancer Therapeutics.

To bridge to gap between science and medicine, as an active translational researcher, over the last three decades, I have spent over 35,000 hours poring over the latest scientific discov­eries, conferring with scientists, and translating many of their discoveries into promising medical therapies. Cancer patients from all over the world have bene­fited from my deep under­standing of cancer cell biology and years of clinical experience.

Treating cancer takes extreme focus. Doctors must be willing to devote a substantial amount of their time, energy, and expertise to each patient individually. This is not easy to do when there are too many patients to take care of. Because of this, I only accept a small number of patients to be under my care. This way, I can provide care that is highly individualized, extremely focused, and more hands-on compared to many of the high-volume alternative (or conventional) cancer clinics.

Treatment cost:

According to HealNavigator.com, treatment at the popular alternative cancer clinics in Mexico, Europe, and Asia costs between $7,000 and $20,000 per week. Besides the expense, in my expert medical opinion, many of these clinics lack sufficient understanding of the complex biology of cancer. This can put patients at risk of treatment failure because the clinics fail to target key survival mechanisms of cancer.

Here is a breakdown of costs at our clinic in Mout Dora, Florida:

• • Initial 2-hour consultation via videoconference: $1500 (one-time fee)
  • Monthly medical management fee: $2500 (includes custom-synthesized syrosingopine)
  • Weekly in-office treatment: $5000
  • Supplements and medications: $300 per month
  • PET/CT scan and Signatera™ blood test: $1430 per month

Lower cost: Added all up, after the initial consultation fee, the cost to be under our care is $6100 per week (vs. $7,000 and $20,000 per week). This includes the cost of the PET/CT scan and Signatera™ blood test to monitor treatment progress. Most patients require 3-4 months of treatment to achieve remission.

Types of cancers treated:

We treat the cancers listed below at stage 3 or 4. We do not treat stage 1 or 2 cancers, nor do we treat hematologic (blood) cancers, such as leukemia, lymphoma, multiple myeloma.

• • Bladder
  • Brain
  • Breast
  • Cervical
  • Colorectal
  • Esophageal
  • Germinoma
  • Head & neck
  • Kidney
  • Liver
  • Lung
  • Melanoma
  • Ovarian
  • Pancreatic
  • Prostate
  • Sarcoma
  • Stomach
  • Testicular
  • Thyroid
  • Uterine

Treatment expectations:

Moving forward, it is important to have proper treatment expectations. For those cancer patients that we accept into our practice, the treatment goal is “curative” (achieving remission and long-term survival) and not “palliative” (buying a bit more time and trying to help maintain some quality of life). In our many years of treating advanced-stage cancer, however, we have found the following conditions associated with a less favorable prognosis and greater difficulty in achieving remission and long-term survival:

• • Markedly elevated ferritin (iron)
  • Markedly elevated inflammatory markers (hs-CRP, homocysteine, fibrinogen)
  • Severely compromised kidney function (markedly elevated BUN & creatinine) and/or liver function (markedly elevated AST & ALT)
  • Severe anemia (very low hemoglobin)
  • Hyponatremia (low blood sodium)
  • Hypoalbuminemia (low blood albumin)
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Markedly elevated D-Dimer
  • Jaundice (yellow tint to the skin or eyes caused by markedly elevated bilirubin)
  • Severe cachexia (muscle wasting)
  • Severe ascites (fluid in the abdomen), pleural effusion (fluid between the lungs and chest wall), and/or anasarca (generalized swelling throughout the body)
  • Uncontrollable pain
  • Uncontrollable nausea/vomiting
  • Resting respiratory rate >20 breaths per minute
  • Disabled and incapable of caring for oneself
  • Inability to travel to our office for treatment

Strategic alliance:

Because proper diet and lifestyle play an integral role in the recovery from cancer, we are partnered with Matthew White, owner of Breakthrough Cancer Coaching (click here). Mr. White and his company provide support and instruction to cancer patients in the crucial areas of nutrition, menu planning and shopping lists, exercise guidance, stress reduction, and emotional support. His involvement is an important part of our commitment to helping cancer patients live better and longer. The cost for Breakthrough Cancer Coaching services is a flat rate of $1,000 per month.

Contact Us:

To find out if we are accepting new patients currently, please contact us below.

Name *

First

Last

Email *

Message *

Submit

References:

1. Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY, Maira SM, Moroni C, Lane HA, Hall MN. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells. Cell Rep. 2018 Dec 11;25(11):3047-3058.e4.
2. Jiang L, Wang P, Sun YJ, Wu YJ. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019 Jun 18;38(1):265.
3. Barancik M, Bohacova V, Gibalova L, Sedlak J, Sulova Z, Breier A. Potentiation of anticancer drugs: effects of pentoxifylline on neoplastic cells. Int J Mol Sci. 2012;13(1):369-382.
4. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 2005 Aug;26(8):1009-16.
5. Liu Z, Huang P, Law S, Tian H, Leung W, Xu C. Preventive Effect of Curcumin Against Chemotherapy-Induced Side-Effects. Front Pharmacol. 2018 Nov 27;9:1374.
6. Jeitler M, Michalsen A, Frings D, Hübner M, Fischer M, Koppold-Liebscher DA, Murthy V, Kessler CS. Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review. Front Pharmacol. 2020 Nov 11;11:580656.
7. Runtuwene J, Amitani H, Amitani M, Asakawa A, Cheng KC, Inui A. Hydrogen-water enhances 5-fluorouracil-induced inhibition of colon cancer. PeerJ. 2015 Apr 7;3:e859.
8. Li S, Liao R, Sheng X, et al. Hydrogen Gas in Cancer Treatment. Front Oncol. 2019;9:696.
9. Al-Refai, A. Chemoprotective effect of ascorbic acid on cyclophosphomide induced oral toxicity. Zanco J Med Sci. 2018; 21(1), 1540-1551.
10. Kim DH, Sung B, Kang YJ, Hwang SY, Kim MJ, Yoon JH, Im E, Kim ND. Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells. Int J Oncol. 2015 Dec;47(6):2226-32.
11. Lee I, Boucher Y, Demhartner TJ, Jain RK. Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer. 1994;69(3):492-496.
12. Hannon, G., Tansi, F.L., Hilger, I. and Prina-Mello, A. (2021), The Effects of Localized Heat on the Hallmarks of Cancer. Adv. Therap., 4: 2000267.
13. Ahn CR, Park J, Kim JE, Ahn KS, Kim YW, Jeong M, Kim HJ, Park SH, Baek SH. Cinnamaldehyde and Hyperthermia Co-Treatment Synergistically Induces ROS-Mediated Apoptosis in ACHN Renal Cell Carcinoma Cells. Biomedicines. 2020 Sep 17;8(9):357.
14. Griffin RJ, Okajima K, Barrios B, Song CW. Mild temperature hyperthermia combined with carbogen breathing increases tumor partial pressure of oxygen (pO2) and radiosensitivity. Cancer Res. 1996 Dec 15;56(24):5590-3.
15. Baronzio G, Parmar G, Baronzio M. Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid. Front Oncol. 2015;5:165.
16. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, Messmer K. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992 Jan 15;52(2):487-90.
17. Lee SH, McIntyre D, Honess D, Hulikova A, Pacheco-Torres J, Cerdán S, Swietach P, Harris AL, Griffiths JR. Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo. Br J Cancer. 2018 Aug;119(5):622-630.
18. Wang Y, Liu Y, Du X, Ma H, Yao J. The Anti-Cancer Mechanisms of Berberine: A Review. Cancer Manag Res. 2020;12:695-702.
19. Zhang Q, Zhu B, Li Y. Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. Front Immunol. 2017 Feb 2;8:71.
20. Hamsa TP, Kuttan G. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol. 2012 Jan;35(1):57-70.
21. Liu Y, Fang S, Sun Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2016 Nov 18;480(3):415-421.
22. Kamran MZ, Gude RP. Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother. 2013 Jun;67(5):399-405.
23. Tripathi SK, Biswal BK. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent. Pharmacol Res. 2020 Jun;156:104772.
24. Stanley G, Harvey K, Slivova V, Jiang J, Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem Biophys Res Commun. 2005 Apr 29;330(1):46-52.
25. Kim JH, Shin BC, Park WS, Lee J, Kuh HJ. Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts. Cancer Sci. 2017;108(12):2470-2477.
26. Holsworth RE Jr, Cho YI, Weidman J. Effect of hydration on whole blood viscosity in firefighters. Altern Ther Health Med. 2013 Jul-Aug;19(4):44-9.
27. Pavan R, Jain S, Shraddha, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203.
28. Lipinski B. Iron-induced parafibrin formation in tumors fosters immune evasion.
29. Altaf F, Wu S, Kasim V. Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy. Front Mol Biosci. 2021;8:680397.
30. Pichon A, Connes P, Quidu P, Marchant D, Brunet J, Levy BI, Vilar J, Safeukui I, Cymbalista F, Maignan M, Richalet JP, Favret F. Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics. Eur Respir J. 2012 Dec;40(6):1401-9.
31. Xin G, Wei Z, Ji C, et al. Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. Sci Rep. 2016;6:36222.
32. Berman W Jr, Berman N, Pathak D, Wood SC. Effects of pentoxifylline (Trental) on blood flow, viscosity, and oxygen transport in young adults with inoperable cyanotic congenital heart disease. Pediatr Cardiol. 1994 Mar-Apr;15(2):66-70.
33. Yip NK, Ho WS. Berberine induces apoptosis via the mitochondrial pathway in liver cancer cells. Oncol Rep. 2013 Sep;30(3):1107-12.
34. Wu X, Jiang L, Zhang Z, He Y, Teng Y, Li J, Yuan S, Pan Y, Liang H, Yang H, Zhou P. Pancreatic cancer cell apoptosis is induced by a proteoglycan extracted from Ganoderma lucidum. Oncol Lett. 2021 Jan;21(1):34.
35. Ong CP. High Dose Vitamin C and Low Dose Chemo Treatment. J Cancer Sci. 2018;5(1): 4.
36. Cham, B. (2017) Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies. International Journal of Clinical Medicine, 8, 692-713.
37. Liu J, Liu P, Xu T, et al. Berberine Induces Autophagic Cell Death in Acute Lymphoblastic Leukemia by Inactivating AKT/mTORC1 Signaling. Drug Des Devel Ther. 2020;14:1813-1823.
38. Wang Y, Wang JW, Xiao X, Shan Y, Xue B, Jiang G, He Q, Chen J, Xu HG, Zhao RX, Werle KD, Cui R, Liang J, Li YL, Xu ZX. Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis. 2013 Oct 3;4(10):e824.
39. Castellanos-Esparza YC, Wu S, Huang L, Buquet C, Shen R, Sanchez-Gonzalez B, García Latorre EA, Boyer O, Varin R, Jiménez-Zamudio LA, Janin A, Vannier JP, Li H, Lu H. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246-1254.
40. Chafe S, Vizeacoumar F, Venkateswaran G, Nemirovsky O, Awrey S, et.al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Science Advances. 27 Aug 2021: Vol. 7, No. 35, eabj0364.
41. Said HM, Hagemann C, Carta F, Katzer A, Polat B, Staab A, Scozzafava A, Anacker J, Vince GH, Flentje M, Supuran CT. Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma. Bioorg Med Chem. 2013 Jul 1;21(13):3949-57.
42. Yamaguchi Y, Kasukabe T, Kumakura S. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol. 2018 Mar;52(3):1011-1022.
43. Afolabi LO, Bi J, Chen L, Wan X. A natural product, Piperlongumine (PL), increases tumor cells sensitivity to NK cell killing. Int Immunopharmacol. 2021 Jul;96:107658.
44. Chang CJ, Chen YY, Lu CC, Lin CS, Martel J, Tsai SH, Ko YF, Huang TT, Ojcius DM, Young JD, Lai HC. Ganoderma lucidum stimulates NK cell cytotoxicity by inducing NKG2D/NCR activation and secretion of perforin and granulysin. Innate Immun. 2014 Apr;20(3):301-11.
45. Mojadadi, Shafi et al. Immunomodulatory Effects of Ganoderma lucidum (W. Curt.:Fr.) P. Karst. (Aphyllophoromycetideae) on CD4+/CD8+ Tumor Infiltrating Lymphocytes in Breast-Cancer-Bearing Mice. International Journal of Medicinal Mushrooms8 (2006): 315-320.
46. Song M, Li ZH, Gu HS, Tang RY, Zhang R, Zhu YL, Liu JL, Zhang JJ, Wang LY. Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis. J Immunol Res. 2021 Mar 5;2021:6696606.
47. Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia. 2014;30(8):531-539.
48. Liu L, Fan J, Ai G, Liu J, Luo N, Li C, Cheng Z. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 2019 Jul 18;52(1):37.
49. Wang L, Qin X, Liang J, Ge P. Induction of Pyroptosis: A Promising Strategy for Cancer Treatment. Front Oncol. 2021 Feb 26;11:635774.
50. Zhang C, Sheng J, Li G, et al. Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review. Front Pharmacol. 2020;10:1461.
51. Lee D, Kim IY, Saha S, Choi KS. Paraptosis in the anti-cancer arsenal of natural products. Pharmacol Ther. 2016 Jun;162:120-33.
52. Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL, McGuckian C, Wade EA, Kato JI, Grassi D, Wentworth M, Burd CE, Arriaga EA, Ladiges WL, Tchkonia T, Kirkland JL, Robbins PD, Niedernhofer LJ. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018 Oct;36:18-28.
53. Wang Y, Chang J, Liu X, et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging (Albany NY). 2016;8(11):2915-2926.
54. Fiorillo M, Tóth F, Sotgia F, Lisanti MP. Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). Aging (Albany NY). 2019 Apr 19;11(8):2202-2216.